Market Leadership in Sight as Eli Lilly’s Oral ...

By Rene Pretorius

April 21, 2025

Summary Eli Lilly's oral GLP-1 medication, orforglipron, has completed a Phas...
Environmental Exposures and Pediatric Thyroid Cancer Risk: Key Findings from ...
Capivasertib Cost-Effectiveness in Advanced Breast Cancer
Reserve Antibiotics Benefits: G-BA Designates Meropenem/Vaborbactam as Critic...
NICE Grants Conditional Robotic Surgery Approval to Enhance Patient Care and ...
Sugary Drinks Cancer Risk: Women Face Higher Oral Cavity Cancer Threat
Cost-Effective HIV PrEP: CAB-LA Transforms Prevention
Global Health Limitations: A Critical Assessment of Structural Constraints an...
Neoadjuvant Immunotherapy Efficacy: Enhancing Treatment Strategies for Head a...
Enhancing UK Clinical Trials Inclusivity: Opportunities and Innovations in Me...
Cost-Effective Interventions for HIV, Malaria, Syphilis, and TB in 128 Countries
Advancing Early Childhood Health: PureHealth’s Partnership with Abu Dha...
Challenges in Accelerating Innovative Paediatric Medicine